Co-association of methotrexate and SPIONs into anti-CD64 antibody-conjugated PLGA nanoparticles for theranostic application

被引:65
作者
Moura, Catarina Costa [1 ,2 ]
Segundo, Marcela A. [1 ]
das Neves, Jose [3 ,4 ]
Reis, Salette [1 ]
Sarmento, Bruno [3 ,4 ]
机构
[1] Univ Porto, Fac Pharm, Dept Chem Sci, REQUIMTE, P-4150180 Oporto, Portugal
[2] Univ Porto, Fac Engn, P-4150180 Oporto, Portugal
[3] Inst Ciencias Saude Norte, Inst Invest & Formacao Avancada Ciencias & Tecnol, CESPU, Gandra PRD, Portugal
[4] Univ Porto, INEB Inst Biomed Engn, P-4150180 Oporto, Portugal
关键词
Fc gamma RI; methotrexate; poly(lactic-co-glycolic acid); superparamagnetic iron oxide nanoparticles; targeted drug delivery; IRON-OXIDE NANOPARTICLES; RHEUMATOID-ARTHRITIS; CANCER; DELIVERY; THERAPY;
D O I
10.2147/IJN.S68440
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Background: Rheumatoid arthritis (RA) is an autoimmune disease with severe consequences for the quality of life of sufferers. Regrettably, the inflammatory process involved remains unclear, and finding successful therapies as well as new means for its early diagnosis have proved to be daunting tasks. As macrophages are strongly associated with RA inflammation, effective diagnosis and therapy may encompass the ability to target these cells. In this work, a new approach for targeted therapy and imaging of RA was developed based on the use of multifunctional polymeric nanoparticles. Methods: Poly(lactic-co-glycolic acid) nanoparticles were prepared using a single emulsion-evaporation method and comprised the co-association of superparamagnetic iron oxide nanoparticles (SPIONs) and methotrexate. The nanoparticles were further functionalized with an antibody against the macrophage-specific receptor, CD64, which is overexpressed at sites of RA. The devised nanoparticles were characterized for mean particle size, polydispersity index, zeta potential, and morphology, as well as the association of SPIONs, methotrexate, and the anti-CD64 antibody. Lastly, the cytotoxicity of the developed nanoparticles was assessed in RAW 264.7 cells using standard MTT and LDH assays. Results: The nanoparticles had a mean diameter in the range of 130-200 nm and zeta potential values ranging from -32 mV to -16 mV. Association with either methotrexate or SPIONs did not significantly affect the properties of the nanoparticles. Conjugation with the anti-CD64 antibody, in turn, caused a slight increase in size and surface charge. Transmission electron microscopy confirmed the association of SPIONs within the poly(lactic-co-glycolic acid) matrix. Both anti-CD64 and methotrexate association were confirmed by Fourier transform infrared spectroscopy, and quantified yielding values as high as 36% and 79%, respectively. In vitro toxicity studies confirmed the methotrexate-loaded nanosystem to be more effective than the free drug. Conclusion: Multifunctional anti-CD64-conjugated poly(lactic-co-glycolic acid) nanoparticles for the combined delivery of methotrexate and SPIONs were successfully prepared and characterized. This nanosystem has the potential to provide a new theranostic approach for the management of RA.
引用
收藏
页码:4911 / 4922
页数:12
相关论文
共 27 条
[1]   A review of therapeutic challenges and achievements of methotrexate delivery systems for treatment of cancer and rheumatoid arthritis [J].
Abolmaali, Samira Sadat ;
Tamaddon, Ali Mohammad ;
Dinarvand, Rassoul .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (05) :1115-1130
[2]  
Albanese A, 2012, ANNU REV BIOMED ENG, V14, P1, DOI [10.1146/annurev-bioeng-071811-150124, 10.1146/annurev.bioeng-071811-150124]
[3]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[4]   Design of surface-modified poly(D,L-lactide-co-glycolide) nanoparticles for targeted drug delivery to bone [J].
Choi, Sung-Wook ;
Kim, Jung-Hyun .
JOURNAL OF CONTROLLED RELEASE, 2007, 122 (01) :24-30
[5]   Differential tumor cell targeting of anti-HER2 (Herceptin®) and anti-CD20 (Mabthera®) coupled nanoparticles [J].
Cirstoiu-Hapca, A. ;
Bossy-Nobs, L. ;
Buchegger, F. ;
Gurny, R. ;
Delie, F. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2007, 331 (02) :190-196
[6]   My Treatment Approach to Rheumatoid Arthritis [J].
Davis, John M., III ;
Matteson, Eric L. .
MAYO CLINIC PROCEEDINGS, 2012, 87 (07) :659-673
[7]   Cancer nanotechnology: Opportunities and challenges [J].
Ferrari, M .
NATURE REVIEWS CANCER, 2005, 5 (03) :161-171
[8]   Evolving concepts of rheumatoid arthritis [J].
Firestein, GS .
NATURE, 2003, 423 (6937) :356-361
[9]   Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody [J].
Kocbek, Petra ;
Obermajer, Natasa ;
Cegnar, Mateja ;
Kos, Janko ;
Kristl, Julijana .
JOURNAL OF CONTROLLED RELEASE, 2007, 120 (1-2) :18-26
[10]   Methotrexate-modified superparamagnetic nanoparticles and their intracellular uptake into human cancer cells [J].
Kohler, N ;
Sun, C ;
Wang, J ;
Zhang, MQ .
LANGMUIR, 2005, 21 (19) :8858-8864